Comparative cardiovascular safety with janus kinase inhibitors and biological disease-modifying antirheumatic drugs as used in clinical practice: an observational cohort study from Sweden in patients with rheumatoid arthritis

OBJECTIVES: To compare the incidence of cardiovascular (CV) events in rheumatoid arthritis (RA) treated with janus kinase inhibitors (JAKi), tumour necrosis factor inhibitors (TNFi), or other biological disease-modifying antirheumatic drugs (bDMARDs), in clinical practice, and to contextualise these...

Descripción completa

Detalles Bibliográficos
Autores principales: Bower, Hannah, Frisell, Thomas, di Giuseppe, Daniela, Delcoigne, Benedicte, Askling, Johan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10668277/
https://www.ncbi.nlm.nih.gov/pubmed/37996125
http://dx.doi.org/10.1136/rmdopen-2023-003630

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10668277/
https://www.ncbi.nlm.nih.gov/pubmed/37996125
http://dx.doi.org/10.1136/rmdopen-2023-003630

Ejemplares similares